Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (377)	1/4/2003 5:49:47 PM
From: Czechsinthemail	Read Replies (1) \| Respond to of 598

Tularik Inc. to Present at the JP Morgan H&Q 21st Annual Healthcare Conference Friday January 3, 6:23 pm ET SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 3, 2003-- Tularik Inc. (Nasdaq:TLRK - News) announced today that David V. Goeddel, Ph.D., Chief Executive Officer, will present at the JP Morgan H&Q 21st Annual Healthcare Conference on Wednesday, January 8, 2003 at 3:00 p.m. PST at the Westin St. Francis Hotel in San Francisco. The presentation will be webcast and may be accessed at the Company's website, www.tularik.com, under the Investors/Media tab. In addition, an archived version of the webcast will be available on the Company's website for at least 10 days. About Tularik Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has three drug candidates in clinical trials. T67 is moving into a pivotal Phase 2/3 study for the treatment of Hepatocellular Carcinoma (HCC) and T607 is in four Phase 2 trials for the treatment of HCC, non-Hodgkin's lymphoma, ovarian cancer and gastric cancer. T487, for the treatment of inflammatory diseases, is in a Phase 1 trial to evaluate safety. For more information, visit Tularik's Internet website at www.tularik.com. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Tularik to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in Tularik's SEC reports, including the report on Form 10-Q for the quarter ended September 30, 2002 and the report on Form 10-K for the year ended December 31, 2001. Tularik does not undertake any obligation to update forward-looking statements. -------------------------------------------------------------------------------- Contact: Tularik Inc. Traci McCarty, 650/825-7182 (investors/media) biz.yahoo.com